Hi Christine,
I am writing to follow-up on a recent email introducing you to SQ Innovation, a medical devices manufacturer that has developed a novel drug-device combination for treating fluid overload in adult patients with chronic heart failure.
Heart failure is the second leading cause of inpatient treatment for Medicare patients, and fluid overload is a major contributor to treatment costs, because it is typically treated with IV diuretics over a several day in-patient hospital stay. SQ Innovation’s new product, Lasix® ONYU, provides patients with effective diuretic treatment without the need for hospital admission. It provides hospital IV-strength diuresis for at-home use, improving the process for patients, healthcare providers, and payers.
The patented device design uses a reusable motorized component and disposable cartridge, which minimizes waste and creates cost-effective treatment option. The company’s highly concentrated formulation of Furosemide is also patented, offering additional intellectual property protection.
SQ Innovation has received tentative approval from the FDA and is finalizing their packaging and commercial infrastructure for launch which is scheduled for October 2025. They have partnerships in place several distributors, and eight hospital systems have already committed to the program upon launch.
With a market potential of more than $1B, a launch that is just months away, and a plan that will have the company reaching break even by the end of 2026, SQ Innovation offers a unique opportunity for life sciences investors.
If you’d like to learn more about SQ Innovation, please respond to this email, and I will put you in touch with company leaders who will be happy to share a non-confidential deck and schedule a meeting.
Kind regards,
Elizabeth
Elizabeth Addonizio
FORCE Family Office
1460 Broadway
New York, N.Y. 10036
All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory body. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical facts and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.